source
- FDA approves oral decitabine/cedazuridine plus venetoclax for older AML patients unable to tolerate intensive chemoThe FDA has approved the oral combination of decitabine/cedazuridine (Inqovi) with venetoclax (Venclexta) for adults with newly diagnosed acute myeloid leukemia who are at least 75 years old or hav…
- FDA approves all-oral decitabine/cedazuridine plus venetoclax for older or unfit AML patientsThe FDA has granted approval for the combination of decitabine and cedazuridine (Inqovi) with venetoclax (Venclexta) to treat newly diagnosed acute myeloid leukemia in adults who are at least 75 ye…